Amg 581
Schizophrenia or Schizoaffective Disorder
AmgenPhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Schizophrenia or Schizoaffective Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MIDAZOLAM Amgen | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →